Macular degeneration is a common eye condition in an ageing population. Chances are that you have a family member or friend who is currently receiving injections for treatment of macular degeneration.
Anti-VEGF injections have been an effective mainstay treatment for neovascular (wet) age-related macular degeneration for over a decade now. Over the years, patients with macular degeneration may have received injections from their treating ophthalmologist with endothelial growth factor (VEGF) inhibitor such as Eylea® (aflibercept).
A new intravitreal injection, Eylea® HD (aflibercept) 8mg, became available on the Pharmaceutical Benefits Scheme (PBS) on 1 October 2024 for treatment of neovascular macular degeneration. It can also be used to treat diabetic macular oedema, a common condition in people diagnosed with diabetes.
Eylea 8mg contains four times greater molar concentration of the active ingredient, aflibercept compared to the original Eylea formulation. This is an important advancement in the armamentarium of macular degeneration treatment. With the higher molar dose, patients may require fewer injections, with each injection providing longer-lasting disease control.
Clinical trial results with Eylea HD 8 mg are impressive. Some patients have been able to maintain their vision with an injection every 3-4 months.
Many patients at City Eye Centre have now received Eylea HD 8mg and patients have reported excellent visual improvement. More patients will be switched over to the new injection in coming months. If you would like further information on how this new intravitreal injection may help you, please contact us on 07 3831 6888 or email us at appointments@cityeye.com.au
.